Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis
- PMID: 32368869
- PMCID: PMC7641910
- DOI: 10.1002/art.41302
Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis
Figures

Comment on
-
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis.Arthritis Rheumatol. 2020 Aug;72(8):1350-1360. doi: 10.1002/art.41294. Epub 2020 Jul 17. Arthritis Rheumatol. 2020. PMID: 32336038 Free PMC article. Clinical Trial.
References
-
- Ruhl T, et al., The endocannabinoid receptors CB1 and CB2 affect the regenerative potential of adipose tissue MSCs. Exp Cell Res, 2020: p. 111881. - PubMed
-
- Tanasescu R and Constantinescu CS, Cannabinoids and the immune system: An overview. Immunobiology, 2010. 215(8): p. 588–597. - PubMed
-
- Galve-Roperh I, et al., Cannabinoid receptor signaling in progenitor/stem cell proliferation and differentiation. Prog Lipid Res, 2013. 52(4): p. 633–50. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical